Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

E0550000

Epirubicin hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

4′-Epidoxorubicin hydrochloride, Epidoxorubicin hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C27H29NO11 · HCl
Numéro CAS:
56390-09-1
Poids moléculaire :
579.98
Numéro MDL:
MFCD00941448
Code UNSPSC :
41116107
ID de substance PubChem :
329798975
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

epirubicin

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

Cl.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO

InChI

1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22-,27-;/m0./s1

Clé InChI

MWWSFMDVAYGXBV-FGBSZODSSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Epirubicin hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Cell-permeable anthracycline antitumor antibiotic. Antineoplastic. A stereoisomer of doxorubicin that exhibits reduced cardiotoxicity. Its antitumor actions are mediated by targeting topoisomerase II.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Danger

Mentions de danger

H302,H340,H350,H360

Classification des risques

Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 8

1 of 8

Paclitaxel European Pharmacopoeia (EP) Reference Standard

Y0000698

Paclitaxel

5-Fluorouracil analytical standard

Supelco

03738

5-Fluorouracil

USP

USP

1225758

Doxorubicinone

Cisplatin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1624

Cisplatin

Etoposide synthetic, 95.0-105.0%, powder

Sigma-Aldrich

E1383

Etoposide

Metformin hydrochloride Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1084

Metformin hydrochloride

Doxorubicine hydrochloride 98.0-102.0% (HPLC)

Sigma-Aldrich

D1515

Doxorubicine hydrochloride

Quercetin ≥95% (HPLC), solid

Sigma-Aldrich

Q4951

Quercetin

Gunter von Minckwitz et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(28), 3531-3539 (2013-08-28)
Bisphosphonates prevent skeletal-related events in patients with metastatic breast cancer. Their effect in early breast cancer is controversial. Ibandronate is an orally and intravenously available amino-bisphosphonate with a favorable toxicity profile. It therefore qualifies as potential agent for adjuvant use.
Hung-Wei Yang et al.
Biomaterials, 34(29), 7204-7214 (2013-06-27)
Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate
Yi Zhang et al.
Toxicology letters, 222(1), 1-9 (2013-07-13)
Epirubicin is widely used in osteosarcoma chemotherapy. Growing evidence indicates that the microRNA (miRNA) expression levels which are induced by chemotherapeutic agents play an important role in osteosarcoma development and progression. In this study we investigate the alterations of miRNA
Sarah N Hamilton et al.
International journal of radiation oncology, biology, physics, 87(4), 719-725 (2013-09-05)
To review the treatment and outcomes of patients with primary cutaneous B-cell lymphoma (CBCL). Clinical characteristics, treatment, and outcomes were analyzed for all patients referred to our institution from 1981 through 2011 with primary CBCL without extracutaneous or distant nodal
Chikako Suzuki et al.
Medical oncology (Northwood, London, England), 30(1), 415-415 (2013-01-17)
The aim of this was to determine whether the change of size observed at the first response evaluation after initiation of first-line combination chemotherapy correlates with overall survival (OS) in patients with metastatic breast cancer (MBC). The change in size
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique